Szymaniec J, Potocka Z, Rogala E, Socha B
Arch Immunol Ther Exp (Warsz). 1979;27(6):871-3.
Trasylol in a single dose 100000 i.u. was administered intravenously to 22 patients suffering from bronchial asthma. Pulmonary function was evaluated by the subjects self-comfort, physical examination, spirometric measurements (VC, FEV1, FEV1%, MCBind.) and blood gas analysis (pH PCO2, PO2, SaO2). In half of the patients after Trasylol administration, a diminished dyspnoea and bronchospasm were observed. Analysis of blood gases indicated some decrease of PCO2, and an increase of PO2 and pH. In spirometric study no statistically significant differences, either before or after Trasylol administration, were noticed. Trasylol treatment may be applied for asthmatic patients especially those with severe disturbances in gas exchange.
给22例支气管哮喘患者静脉注射单次剂量100000国际单位的抑肽酶。通过受试者的自我舒适度、体格检查、肺量计测量(肺活量、第一秒用力呼气量、第一秒用力呼气量百分比、最大呼气中期流速)和血气分析(pH值、二氧化碳分压、氧分压、血氧饱和度)来评估肺功能。在一半的患者中,注射抑肽酶后观察到呼吸困难和支气管痉挛减轻。血气分析表明二氧化碳分压有所降低,氧分压和pH值有所升高。在肺量计研究中,未发现注射抑肽酶前后有统计学上的显著差异。抑肽酶治疗可应用于哮喘患者,尤其是那些气体交换严重紊乱的患者。